Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects
The DOI matches its Crossref record; 28 of the 31 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are both incretin hormones regulating postprandial insulin secretion. Their relative importance in this respect under normal physiological conditions is unclear, however, and the aim of the present investigation was to evaluate this. Eight healthy male volunteers (mean age: 23 (range 20-25) years; mean body mass index: 22.2 (range 19.3-25.4) kg/m2) participated in studies involving stepwise glucose clamping at fasting plasma glucose levels and at 6 and 7 mmol/l. Physiological amounts of either GIP (1.5 pmol/kg/min), GLP-1(7-36)amide (0.33 pmol/kg/min) or saline were infused for three periods of 30 min at each glucose level, with 1 h "washout" between the infusions. On a separate day, a standard meal test (566 kcal) was performed. During the meal test, peak insulin concentrations were observed after 30 min and amounted to 223+/-27 pmol/l. Glucose+saline infusions induced only minor increases in insulin concentrations. GLP-1 and GIP infusions induced significant and similar increases at fasting glucose levels and at 6 mmol/l. At 7 mmol/l, further increases were seen, with GLP-1 effects exceeding those of GIP. Insulin concentrations at the end of the three infusion periods (60, 150 and 240 min) during the GIP clamp amounted to 53+/-5, 79+/-8 and 113+/-15 pmol/l, respectively. Corresponding results were 47+/-7, 95+/-10 and 171+/-21 pmol/l, respectively, during the GLP-1 clamp. C-peptide responses were similar. Total and intact incretin hormone concentrations during the clamp studies were higher compared to the meal test, but within physiological limits. Glucose infusion alone significantly inhibited glucagon secretion, which was further inhibited by GLP-1 but not by GIP infusion. We conclude that during normal physiological plasma glucose levels, glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide contribute nearly equally to the incretin effect in humans, because their differences in concentration and potency outweigh each other.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As a result, an early-onset of reactive hypoglycemia occurs due to the incretin effect related to glucose loading occurs.[27, 28]”
From Postprandial Reactive Hypoglycemia (2019) · cites this paper as [28]
In the citing paper
“The early studies by Nauck and Holst have shown that the actions of GLP-1 and GIP on insulin secretion are nearly equal and additive in healthy humans [20,21]”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [20]
Citations
Cites
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans
Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994) · Diabetes · doi:10.2337/diab.43.4.535 · Cited by 919
Self-citationVilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 884
Self-citationNAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874
Scrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793
Abnormal Alpha-Cell Function in Diabetes: Response to Carbohydrate and Protein Ingestion
Müller, W. A., Faloona, G. R., Aguilar-Parada, E., & Unger, R. H. (1970) · New England Journal of Medicine · doi:10.1056/nejm197007162830301 · Cited by 626
FEHMANN, H.-C., GÖKE, R., & GÖKE, B. (1995) · Endocrine Reviews · doi:10.1210/edrv-16-3-390 · Cited by 528
Nauck, M. A. (1993) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.76.4.912 · Cited by 506
Miyawaki, K., Yamada, Y., Yano, H., Niwa, H., Ban, N., Ihara, Y., Kubota, A., Fujimoto, S., Kajikawa, M., Kuroe, A., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.14843 · Cited by 454
Deacon, C. F., Nauck, M. A., Meier, J., Hücking, K., & Holst, J. J. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.10.6855 · Cited by 401
Self-citation
Cited by
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Self-citationConsumption of high-fructose corn syrup in beverages may play a role in the epidemic of obesity
Bray, G. A., Nielsen, S. J., & Popkin, B. M. (2004) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/79.4.537 · Cited by 1,990
Avena, N. M., Rada, P., & Hoebel, B. G. (2008) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2007.04.019 · Cited by 1,358
Incretin hormones: Their role in health and disease
Nauck, M. A., & Meier, J. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13129 · Cited by 950
The role of incretins in glucose homeostasis and diabetes treatment
Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824
“The elimination rates of GLP-1 are similar in T2DM and nondiabetic subjects, and, as with GIP, more rapid degradation of GLP-1 is unlikely to be a contributory cause for glucose-responsiveness in T2DM (Vilsbøll et al., 2003a).”
Background
Metadata
- Authors
- Vilsbøll, T., Krarup, T., Madsbad, S., & Holst, J. J.
- Affiliations
- University of Copenhagen (DK)
- Corresponding author
- Vilsbøll, Tina
- Venue
- Regulatory Peptides
- Publisher
- Elsevier BV
- Published
- 2003-07
- Volume
- 114
- Issue
- 2-3
- Pages
- 115-121
- ISSN
- 0167-0115 (ISSN-L)
- OpenAlex
- W2057154465
- Cited by
- 430
- References
- 31
- Citations by year
- 2026: 11 · 2025: 13 · 2024: 16 · 2023: 12 · 2022: 13 · 2021: 13 · 2020: 18 · 2019: 27 · 2018: 26 · 2017: 16 · 2016: 16 · 2015: 29 · 2014: 31 · 2013: 25 · 2012: 14
- FWCI
- 8.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- Regulatory Peptides (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Funders
- Novo Nordisk Fonden
- Diabetesforeningen
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, incretin effect, insulin secretion, postprandial blood glucose, test meal, C-peptide, glucagon secretion, GLP-1(7-36), healthy volunteers, incretins, beta-cell function
- MeSH terms
- Insulin Secretion, Adult, Blood Glucose, C-Peptide, Gastric Inhibitory Polypeptide, Glucagon, Glucose, Humans, Insulin, Male, Peptide Fragments, Protein Precursors, Reference Values, Postprandial Period, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. https://app.cochat.ai/papers/10.1016/s0167-0115(03)00111-3
- The paper
- Vilsbøll, T., Krarup, T., Madsbad, S., & Holst, J. J. (2003). Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regulatory Peptides. https://doi.org/10.1016/s0167-0115(03)00111-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.